KRMD Stock Overview
Develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KRMD from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
KORU Medical Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$5.05 |
| 52 Week Low | US$1.86 |
| Beta | 0.87 |
| 1 Month Change | 25.00% |
| 3 Month Change | -38.04% |
| 1 Year Change | 23.38% |
| 3 Year Change | 9.62% |
| 5 Year Change | -74.58% |
| Change since IPO | 7,025.00% |
Recent News & Updates
Recent updates
KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Mar 05
KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10
Nov 16Impressive Turnaround At KORU Medical
Nov 06We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow
Aug 29KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares
Jul 30Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues
Feb 15We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely
Sep 21Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower
Jul 14We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate
Sep 27Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans
Oct 27Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report
Aug 14Shareholder Returns
| KRMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 7.1% | 1.5% | 2.8% |
| 1Y | 23.4% | 8.1% | 9.3% |
Return vs Industry: KRMD exceeded the US Medical Equipment industry which returned 8.1% over the past year.
Return vs Market: KRMD exceeded the US Market which returned 9.3% over the past year.
Price Volatility
| KRMD volatility | |
|---|---|
| KRMD Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: KRMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRMD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 80 | Linda Tharby | www.korumedical.com |
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
KORU Medical Systems, Inc. Fundamentals Summary
| KRMD fundamental statistics | |
|---|---|
| Market cap | US$130.98m |
| Earnings (TTM) | -US$6.07m |
| Revenue (TTM) | US$33.65m |
3.9x
P/S Ratio-21.6x
P/E RatioIs KRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRMD income statement (TTM) | |
|---|---|
| Revenue | US$33.65m |
| Cost of Revenue | US$12.31m |
| Gross Profit | US$21.33m |
| Other Expenses | US$27.40m |
| Earnings | -US$6.07m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 63.40% |
| Net Profit Margin | -18.03% |
| Debt/Equity Ratio | 1.6% |
How did KRMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 16:18 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KORU Medical Systems, Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Kyle Rose | Canaccord Genuity |